Use of Safety Behaviors in Exposure Therapy for Arachnophobia

Not Applicable

Completed

• Conditions: Arachnophobia; Spider Phobia; Specific Phobia
• Interventions: Behavioral: Exposure with faded safety behaviors; Behavioral: Exposure with unfaded safety behaviors; Behavioral: Exposure without safety behaviors

• Registration Number: NCT04470882
• Lead Sponsor: University of Nevada, Reno

Brief Summary

This study examines the impact of safety behaviors (i.e., unnecessary protective actions) on outcomes of exposure therapy for spider phobia. Researchers will compare exposure therapy with (a) no safety behaviors, (b) safety behaviors faded toward the end of treatment, and (c) unfaded safety behaviors.

Detailed Description

Some studies suggest that safety behaviors might undermine the efficacy of exposure therapy (Powers et al., 2010), whereas other studies suggest that there is no difference in exposure therapy outcomes whether or not safety behaviors are used (Deacon et al., 2010). Mixed findings could be explained by the parameters of safety behaviors use, such as whether they are used throughout the full course of therapy or faded toward the end of therapy. This will be the first study to directly compare the impact of faded and unfaded safety behaviors on exposure therapy outcomes. Specifically, researchers will randomize participants with a fear of spiders to receive exposure therapy (a) without safety behavior use, (b) with faded safety behavior use, and (c) with un-faded safety behavior use. Researchers will compare each condition's impact on fear reduction and on the tolerability/acceptability of treatment.

Study Timeline

• Study Start: 2019-02-28
• Study First Submitted: 2019-04-11
• Primary Completion: 2020-04-06
• Study Completion: 2020-04-06
• Study First Submitted QC: 2020-07-09
• Study First Posted: 2020-07-14
• Status Verified: 2021-10
• Last Update Submitted: 2021-10-08
• Last Update Posted: 2021-10-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 59

Inclusion Criteria

• Fluent in English
• Displays sufficiently high fear of spiders, as indicated by responses on (a) a self report questionnaire (the Fear of Spiders Questionnaire) at prescreening, and (b) Behavioral Avoidance Tests at baseline

Exclusion Criteria

• younger than 18 years old

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Exposure with faded safety behaviors	Exposure with faded safety behaviors	Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
Exposure with unfaded safety behaviors	Exposure with unfaded safety behaviors	Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
Exposure without safety behaviors	Exposure without safety behaviors	Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.

Primary Outcome Measures

Name	Time	Method
Behavioral approach test (generalization context) - subjective outcome	Change from baseline up to 4 weeks later (through follow up assessment)	Participants will approach a live, non-poisonous tarantula, placed in a clear tank on a table, at the opposite end of the room. The test is over when the participant has reached the hardest step that they can complete at that time. Steps include walking toward the spider and lowering one hand into the tank.; During this BAT, investigators will assess fear response subjectively by having participants self report their peak fear level (on a 0 to 100 scale).
Behavioral approach test (generalization context) - physiological outcome	Change from baseline up to 4 weeks later (through follow up assessment)	Participants will approach a live, non-poisonous tarantula, placed in a clear tank on a table, at the opposite end of the room. The test is over when the participant has reached the hardest step that they can complete at that time. Steps include walking toward the spider and lowering one hand into the tank.; During this BAT, investigators will assess fear response physiologically by assessing heart rate variability.
Behavioral approach test (treatment context) - subjective outcome	Change from baseline up to 4 weeks later (through follow up assessment)	Participants will approach a live, non-poisonous tarantula, placed on the floor, at the opposite end of the room. The participant will walk toward the spider during this test. The test is over when the participant has reached the hardest step that they can complete at that time.; During this BAT, investigators will assess fear response subjectively by having participants self report their peak fear level (on a 0 to 100 scale).
Fear of Spiders Questionnaire (FSQ)	Change from baseline up to 4 weeks later (through follow up assessment)	Self-report rating scale in which participants rate the extent that they agree with a number of statements that are representative of having a fear of spiders. Sum total scores will be calculated (range 0-108). Higher scores indicate more severe symptom levels.
Armfield and Mattiske Disgust Questionnaire (AMDQ)	Change from baseline up to 4 weeks later (through follow up assessment)	Self-report questionnaire assessing feelings of disgust associated with spiders. Sum total scores will be calculated (range 0-48). Higher scores indicate more severe spider-related disgust.
Spider Phobia Beliefs Questionnaire (SBQ)	Change from baseline up to 4 weeks later (through follow up assessment)	Self-report rating scale assessing the level to which the participant believes a number of cognitions/thoughts commonly associated with spider phobia. An overall average rating will be calculated (range 0-100). Higher average scores indicate greater belief in spider phobic cognitions.
Behavioral approach test (treatment context) - behavioral outcome	Change from baseline up to 4 weeks later (through follow up assessment)	Participants will approach a live, non-poisonous tarantula, placed on the floor, at the opposite end of the room. The participant will walk toward the spider during this test. The test is over when the participant has reached the hardest step that they can complete at that time.; During this BAT, investigators will assess fear response behaviorally by recording the most challenging step completed (range, steps 0 -12).
Behavioral approach test (treatment context) - physiological outcome	Change from baseline up to 4 weeks later (through follow up assessment)	Participants will approach a live, non-poisonous tarantula, placed on the floor, at the opposite end of the room. The participant will walk toward the spider during this test. The test is over when the participant has reached the hardest step that they can complete at that time.; During this BAT, investigators will assess fear response physiologically by assessing heart rate variability.
Behavioral approach test (generalization context) - behavioral outcome	Change from baseline up to 4 weeks later (through follow up assessment)	Participants will approach a live, non-poisonous tarantula, placed in a clear tank on a table, at the opposite end of the room. The test is over when the participant has reached the hardest step that they can complete at that time. Steps include walking toward the spider and lowering one hand into the tank.; During this BAT, investigators will assess fear response behaviorally by recording the most challenging step completed (range, steps 0-21).
Anxiety Disorders Interview Schedule for DSM-5 (ADIS-5)	Change from baseline up to 4 weeks later (through follow up assessment)	Participants will be given a structured interview to identify whether they meet diagnostic criteria for specific phobia. Responses will be coded dichotomously (yes = has diagnosis; no = no diagnosis).

Secondary Outcome Measures

Name	Time	Method
Treatment Acceptability/Adherence Scale (Modified version)	Measured immediately after completing a one-session treatment	Self-report questionnaire assessing the participant's perceptions regarding treatment acceptability and willingness to adhere to treatment procedures. Sum total scores will be calculated (range 10-70). Higher scores indicate greater acceptability/adherence.

Trial Locations

Locations (1)

University of Nevada, Reno; 🇺🇸 Reno, Nevada, United States